Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

1.17.1.4: xanthine dehydrogenase

This is an abbreviated version!
For detailed information about xanthine dehydrogenase, go to the full flat file.

Word Map on EC 1.17.1.4

Reaction

xanthine
+
NAD+
+
H2O
=
Urate
+
NADH
+
H+

Synonyms

AtXDH1, EC 1.1.1.204, EC 1.2.1.37, IAO1, More, NAD-xanthine dehydrogenase, PaoABC, Retinol dehydrogenase, Rosy locus protein, VvXDH, xanthine dehydrogenase, xanthine dehydrogenase-1, xanthine dehydrogenase-2, xanthine dehydrogenase/oxidase, xanthine oxidoreductase, xanthine-NAD oxidoreductase, xanthine/NAD+ oxidoreductase, xanthine:NAD+ oxidoreductase, XDH, XDH/XO, XDH1, XDH2, XdhC, XOR, YagR, YagS, YagT

ECTree

     1 Oxidoreductases
         1.17 Acting on CH or CH2 groups
             1.17.1 With NAD+ or NADP+ as acceptor
                1.17.1.4 xanthine dehydrogenase

Engineering

Engineering on EC 1.17.1.4 - xanthine dehydrogenase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
E1297A
site-directed mutagenis
E831A
site-directed mutagenis
G48D
naturally occuring mutation, drf mutant, missense mutation G143A, i.e. drf1-1 or xdh1-3
G48D/R941Q/T1061I
naturally occuring mutation, identification of 15 potential drf mutants, drf1 mutants contain missense mutations in XDH1, the mutant phenotypes cosegregate with a single missense mutation G143A. Targeted sequencing of XDH1 revealed missense mutations G2822A (resulting in R941Q) and C3182T (resulting in T1061I) in the remaining two mutants, respectively. Identification of a knockout mutant GK-049D04, i.e. xdh1-2, and of knockdown allele in SALK_148364 where a T-DNA is inserted in the 11th intron of XDH1, i.e. xdh1-1. Defense phenotypes of drf mutants, general phenotypes, overview. The loss-of-function single and double mutant lines for atrobhD and atrbohF and the eds1-2 null allele in the Col-0 background are crossed with xdh1-2 to make xdh1 rbohD and xdh1 rbohF, xdh1 eds1 double, and xdh1 rbohD rbohF triple mutant lines
R909A
site-directed mutagenis
R941Q
naturally occuring mutation, drf mutant, missense mutation G2822A, i.e. drf1-2 or xdh1-4
T1061I
naturally occuring mutation, drf mutant, missense mutation C3182T, i.e. drf1-3 or xdh1-5
W364A
site-directed mutagenis
Y421A
site-directed mutagenis
G48D
-
naturally occuring mutation, drf mutant, missense mutation G143A, i.e. drf1-1 or xdh1-3
-
G48D/R941Q/T1061I
-
naturally occuring mutation, identification of 15 potential drf mutants, drf1 mutants contain missense mutations in XDH1, the mutant phenotypes cosegregate with a single missense mutation G143A. Targeted sequencing of XDH1 revealed missense mutations G2822A (resulting in R941Q) and C3182T (resulting in T1061I) in the remaining two mutants, respectively. Identification of a knockout mutant GK-049D04, i.e. xdh1-2, and of knockdown allele in SALK_148364 where a T-DNA is inserted in the 11th intron of XDH1, i.e. xdh1-1. Defense phenotypes of drf mutants, general phenotypes, overview. The loss-of-function single and double mutant lines for atrobhD and atrbohF and the eds1-2 null allele in the Col-0 background are crossed with xdh1-2 to make xdh1 rbohD and xdh1 rbohF, xdh1 eds1 double, and xdh1 rbohD rbohF triple mutant lines
-
R941Q
-
naturally occuring mutation, drf mutant, missense mutation G2822A, i.e. drf1-2 or xdh1-4
-
T1061I
-
naturally occuring mutation, drf mutant, missense mutation C3182T, i.e. drf1-3 or xdh1-5
-
G1011E
-
within the molybdenum domain, no activity without oxidative activation
G353D
-
modifications to the NAD+-NADH-binding sites
S357F
-
modifications to the NAD+-NADH-binding sites
R40K
mutation in subunit PaoC, strong decrease in activity
R440H
mutation in subunit PaoC, strong decrease in activity, crystallization data
E803V
R881M
C535A
-
resistant to conversion from dehydrogenase to oxidase by incubation with 4,4’-dithiodipyridine
C535A/C992R
C535A/C992R/C1316S
C535A/C992R/C1324S
C992R
-
resistant to conversion from dehydrogenase to oxidase by incubation with 4,4’-dithiodipyridine
W335A/F336L
mutant oxidoreductase displaying xanthine oxidase activity
C134A/C136A
-
site-directed mutagenesis, an inactive subunit A mutant
C44A/C47A
-
site-directed mutagenesis, an instable subunit A mutant that cannot be purified
E220R/D517R
-
site-directed mutagenesis, a subunit B mutant that is mainly dimeris incontrast to the tetrameric wild-type enzyme, inactive mutant
E232A
E232Q
site-directed mutagenesis, kred, the limiting rate constant for reduction at high [xanthine], is significantly compromised in the mutant variant E232Q, the mutant exhibits a 12fold decrease in kred, a result that is inconsistent with Glu232 being neutral in the active site of the wild-type enzyme
E730A
E730D
-
no enzymic activity
E730Q
-
no enzymic activity
E730R
-
no enzymic activity
EB232Q
catalytically inactive active site mutant, inactive desulfo enzyme form
Q102A
-
site-directed mutagenesis, a subunit A mutant that shows altered metal content and reduced KM and Kcat with xanthine compared to the wild-type enzyme
Q102G
-
site-directed mutagenesis, a subunit A mutant that shows altered metal content and reduced KM and Kcat with xanthine compared to the wild-type enzyme
Q179A
-
crystal structure determination and analysis, comparison with wild-type enzyme structure, a similar acidic pK for the wild-type and Q179A variants, as well as the metrical parameters of the Mo site and density functional theory calculations, suggested protonation at the equatorial oxo group. Oxidized wild-type and mutant Q179A reveal a similar Mo(VI) ion with each one molybdopterin, Mo=O, Mo-O-, and Mo=S ligand, and a weak Mo-O(E730) bond at alkaline pH
R135C
-
mutation corresponding to human protein variant of a patient suffering from xanthinuria I. Mutation results in an active (alphabeta)2 heterotetrameric form besides an inactive alphabeta heterodimeric form missing the FeSI center
R310K
R310M
R330M
-
the activity with substrate 2-hydroxy-6-methylpurine is only slightly affected
D430H
-
Km (cyanoacetylhydrazone 2-formylquinoxaline-1,4-dioxide) slightly increased compared to wild-type, Vmax (cyanoacetylhydrazone 2-formylquinoxaline-1,4-dioxide) decreased compared to wild-type, Km (xanthine) slightly decreased compared to wild-type, Vmax (xanthine) slightly decreased to wild-type
D431A
-
Km (cyanoacetylhydrazone 2-formylquinoxaline-1,4-dioxide) slightly increased compared to wild-type, Vmax (cyanoacetylhydrazone 2-formylquinoxaline-1,4-dioxide) increased compared to wild-type, Km (xanthine) slightly increased compared to wild-type, Vmax (xanthine) increased to wild-type
G47A
-
Km and Vmax (cyanoacetylhydrazone 2-formylquinoxaline-1,4-dioxide) increased compared to wild-type, Km and Vmax (xanthine) slightly increased compared to wild-type
K1230A
-
Km (cyanoacetylhydrazone 2-formylquinoxaline-1,4-dioxide) 2.5fold increased compared to wild-type, Vmax (cyanoacetylhydrazone 2-formylquinoxaline-1,4-dioxide) decreased compared to wild-type, Km (xanthine) 2fold increased compared to wild-type, Vmax (xanthine) 2fold decreased to wild-type
N352A
-
Km (cyanoacetylhydrazone 2-formylquinoxaline-1,4-dioxide) slightly increased compared to wild-type, Vmax (cyanoacetylhydrazone 2-formylquinoxaline-1,4-dioxide) slightly decreased compared to wild-type, Km (xanthine) slightly increased compared to wild-type, Vmax (xanthine) slightly decreased compared to wild-type
R427E
-
Km (cyanoacetylhydrazone 2-formylquinoxaline-1,4-dioxide) decreased compared to wild-type, Vmax (cyanoacetylhydrazone 2-formylquinoxaline-1,4-dioxide) decreased compared to wild-type, Km (xanthine) slightly increased compared to wild-type, Vmax (xanthine) comparable to wild-type
S1227A
-
Km (cyanoacetylhydrazone 2-formylquinoxaline-1,4-dioxide) 2.5fold increased compared to wild-type, Vmax (cyanoacetylhydrazone 2-formylquinoxaline-1,4-dioxide) decreased compared to wild-type, Km (xanthine) 2fold increased compared to wild-type, Vmax (xanthine) 2fold decreased to wild-type
S360P
-
Km (cyanoacetylhydrazone 2-formylquinoxaline-1,4-dioxide) increased compared to wild-type, Vmax (cyanoacetylhydrazone 2-formylquinoxaline-1,4-dioxide) decreased compared to wild-type, Km (xanthine) 3fold increased compared to wild-type, Vmax (xanthine) 3fold decreased compared to wild-type
additional information